Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI-505 with HDM+ASCT in Multiple Myeloma
NCT02756728Phase 2Terminated
- Sponsor
- BioInvent International
- Start
- May 2016
- Primary completion
- Dec 2016
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bersanlimab in multiple myeloma (MM) (2 arms), sponsored by BioInvent International. Primary endpoints: Safety and feasibility of administering BI-505 in conjunction with HDM+ASCT and Rate of stringent complete response. Started May 2016; status: terminated.
02
Drugs
bersanlimab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02756728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02756728.